Opioid Prescribing in United States Health Systems, 2015 to 2019
Health systems (nonfederal hospitals and clinics) are the second major source for drug expenditure in the United States. Opioids prescribed in these healthcare settings are commonly short-acting opioids that can lead to persistent opioid use. Nevertheless, there are no national data that describe trends in opioid use and the associated expenditure in health systems. Therefore, the objective of this article was to describe opioid use and expenditures in US health systems from 2015 to  2019. (Source: Value in Health)
Source: Value in Health - June 24, 2021 Category: International Medicine & Public Health Authors: Tumader Khouja, Mina Tadrous, Linda Matusiak, Katie Suda Tags: Health Policy Analysis Source Type: research

Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States
The objective of this study was to compare the preferences for EQ-5D-Y-3L obtained from adolescents for themselves to those of adults considering a hypothetical 10-year-old child in Germany, Slovenia, and Spain. (Source: Value in Health)
Source: Value in Health - June 24, 2021 Category: International Medicine & Public Health Authors: Valentina Prevolnik Rupel, Juan M. Ramos-Go ñi, Marko Ogorevc, Simone Kreimeier, Kristina Ludwig, Wolfgang Greiner Tags: Preference-Based Assessments Source Type: research

Patient-Reported Outcomes After Treatment Discontinuation: Commercial Clinical Trial Data From Four Cancer Types
How frequently patient-reported outcome (PRO) data are collected in commercial cancer clinical trials after treatment discontinuation and the quality of that data are poorly understood. We reviewed treatment discontinuation follow-up PRO data collection to learn about trials collecting these data and understand data quality. The review included 4 cancer types representing potential for long- (prostate cancer), medium-/long- (breast cancer), and short-term (pancreatic cancer and hepatocellular carcinoma) follow-up owing to disease trajectory. (Source: Value in Health)
Source: Value in Health - June 24, 2021 Category: International Medicine & Public Health Authors: Bellinda L. King-Kallimanis, Nirosha Mahendraratnam Lederer, Janice Kim, Abhilasha Nair, Erica Horodniceanu, Vishal Bhatnagar, Paul G. Kluetz Tags: Patient-Reported Outcomes Source Type: research

Drug Prices and Value of Oncology Drugs in Italy
The main objective of this study was to evaluate the potential role of efficacy data and other information available at the time of price and reimbursement (P&R) decision-making process within the definition of oncology treatment costs in Italy. (Source: Value in Health)
Source: Value in Health - June 23, 2021 Category: International Medicine & Public Health Authors: Pierluigi Russo, Andrea Marcellusi, Matteo Zanuzzi, Angelica Carletto, Maria Elisabetta Fratto, Giampiero Favato, Tommaso Staniscia, Ferdinando Romano Romano Tags: Health Policy Analysis Source Type: research

Do Centers for Medicare and Medicaid Services Quality Measures Reflect Cost-Effectiveness Evidence?
This study aimed to analyze cost-effectiveness evidence associated with the Centers for Medicare and Medicaid Services quality measures. (Source: Value in Health)
Source: Value in Health - June 19, 2021 Category: International Medicine & Public Health Authors: Timothy J. van Dover, David D. Kim Tags: Brief Report Source Type: research

The CAPACITI Decision-Support Tool for National Immunization Programs
Immunization programs in low-income and middle-income countries (LMICs) are faced with an ever-growing number of vaccines of public health importance recommended by the World Health Organization, while also financing a greater proportion of the program through domestic resources. More than ever, national immunization programs must be equipped to contextualize global guidance and make choices that are best suited to their setting. The CAPACITI decision-support tool has been developed in collaboration with national immunization program decision makers in LMICs to structure and document an evidence-based, context-specific pro...
Source: Value in Health - June 18, 2021 Category: International Medicine & Public Health Authors: Siobhan Botwright, Birgitte K. Giersing, Martin I. Meltzer, Anna-Lea Kahn, Mark Jit, Rob Baltussen, Nathalie El Omeiri, Joseph N.-M. Biey, Kelly L. Moore, Praveen Thokala, Jason M. Mwenda, Melanie Bertram, Raymond C.W. Hutubessy Tags: Methodology Source Type: research

Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials
In this study we characterized HTAs for SAT-based submissions, the use of supplementary EC data and outcomes from HTA review. (Source: Value in Health)
Source: Value in Health - June 8, 2021 Category: International Medicine & Public Health Authors: Dony Patel, Fiona Grimson, Elena Mihaylova, Peter Wagner, Joss Warren, Anke van Engen, Joseph Kim Source Type: research

Long-Term Cost-Effectiveness of Smoking Cessation Interventions in People With Mental Disorders: A Dynamic Decision Analytical Model
The objective of this study is to develop a decision analytical model that estimates long-term cost-effectiveness of smoking cessation interventions in this population. (Source: Value in Health)
Source: Value in Health - June 3, 2021 Category: International Medicine & Public Health Authors: Qi Wu, Simon Gilbody, Jinshuo Li, Han-I Wang, Steve Parrott Tags: Economic Evaluation Source Type: research

Editorial Board
(Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Source Type: research

Table of Contents
(Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Source Type: research

Copyright/Subscription
(Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Source Type: research

AI1 Quantifying Bias in ML-Extracted Variables for Inference in Clinical Oncology
This study assessed the effects of misclassification error in ML-extracted clinical variables when used in statistical analyses. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: J. Lee, M. Estevez, B.D. Segal, A. Sondhi, A.B. Cohen, S.T. Cherng Tags: Artificial Intelligence Method Studies Source Type: research

AI2 The Impact of Including Race and Ethnicity in Risk Prediction Models on Racial Bias
Risk prediction algorithms can support clinical decision-making but there is a lack of consensus on when and how sociodemographic factors, especially the social construct of race/ethnicity, should be included in these algorithms. Our objective is to assess the impact of including race as a predictor in a risk prediction algorithm on racial biases in model performance. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: S. Khor, E.E. Hahn, E.C. Haupt, V. Shankaran, S. Clark, P. Rodriguez, Y. Chen, A. Bansal Source Type: research

AI3 Disease-Free Survival (DFS) As a Surrogate Endpoint for Overall Survival (OS) in Adults with Resectable Esophageal or Gastroesophageal Junction Cancer: A Correlation Meta-Analysis
To evaluate the appropriateness of using DFS as a surrogate for OS in  trials investigating adults with resectable esophageal or gastroesophageal junction cancer (EC/GEJ) receiving therapies in the (neo)adjuvant and perioperative settings. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: L. Leung, M. Kurt, P. Singh, I. Kim, G. Donnellan, S. Kanters Source Type: research

AI4 Comparing Machine-Learning Methods for the Prediction of Major Adverse Limb Events and Mortality after a Percutaneous Intervention
The objective was to formulate, test, and compare the performance of regression-based and machine learning models in the prediction major adverse limb events (MALE) and mortality among patients receiving treatment for lower extremity peripheral artery disease (PAD). (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: L. Gressler, D. Marinac-Dabic, S. Dosreis, P. Goodney, C.D. Mullins, F.T. Shaya Source Type: research

CE1 A Modeled Health Outcomes Evaluation of Darolutamide Plus Androgen Deprivation Therapy for High-Risk NON-Metastatic Castration-Resistant Prostate Cancer in China
Novel antiandrogens have demonstrated clinical benefit for patients with non-metastatic castration resistant prostate cancer (nmCRPC). We modeled the incremental life-years and QALYs of darolutamide+ADT compared to apalutamide+ADT and enzalutamide+ADT, for high-risk nmCRPC, in a Chinese setting. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: J. Ming, Y. Liu, W. Lu, Y. Wu, W. Li, R. Han, S. Hu Tags: Comparative Effectiveness Studies Source Type: research

CE2 Effect of Different Variance Estimation Methods with Inverse Probability Treatment Weights (IPTW) on Comparative Effectiveness Measure in Multiple Sclerosis
The objective of this study was to compare the treatment effects from three different variance estimation methods with stabilized IPTWs on comparative effectiveness between oral fingolimod and injectable Disease Modifying Agents (DMA) users in Multiple Sclerosis (MS). (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: J. Earla, G.J. Hutton, J.D. Thornton, H. Chen, M.L. Johnson, R.R. Aparasu Source Type: research

CE3 Systematic Review and Indirect Comparison of PD-(L)1 Inhibitors in Combination with Platinum-Based Doublet Chemotherapy (PT-DC) for the First-Line Treatment of Non-Squamous, Non-Small-Cell Lung Cancer (nsqNSCLC)
To evaluate relative efficacy and safety of sintilimab compared with other PD-(L)1 inhibitors in combination with platinum-based doublet chemotherapy (PT-DC) for the first-line treatment of nsqNSCLC. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: L. Zhang, Y. Qian, J. Li, C. Cui, L. Chen, S. Qu, S. Lu Source Type: research

CE4 Expanding Evidence Base VS Introducing Heterogeneity in Networks for Network Meta-Analyses: A Simulation Study
This study aimed to explore the trade-off between increasing  the evidence base by including additional studies and increasing the level of heterogeneity in the network considered. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: H. Luttenauer, P. Le Nouveau, A. Gauthier Source Type: research

CN1 Patterns of Utilization and Implementation Experiences of Oncology Monoclonal Antibodies (MABS) Biosimilars in the U.S.: From BOTH Payers and Healthcare Professionals (HCPS) Perspectives
Biosimilars are highly similar to an originator biologic, with no clinically meaningful differences in safety or efficacy. The adoption of biosimilars might provide an opportunity to lower costs and increase patient access to biologics. The current study sought to understand real-world implementation experiences associated with oncology MAbs biosimilars (trastuzumab, rituximab, and bevacizumab) from both payer and healthcare professional (HCP) perspectives. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: J. Yang, K. Blinzler, J. Lankin, M. Maculaitis, A. Shelbaya Tags: Oncology Studies Source Type: research

CN2 Eliciting Unreported Subgroup-Specific Survival from Aggregate Randomized Controlled Trial Data
This study developed an analytical framework to elicit unreported subgroup-specific survival information from aggregate RCT data. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: O. Alagoz, H. Xiao, P. Singh, J. Gricar, M. Dixon, M. Kurt Source Type: research

CN3 It's All in the Family: Microsimulation Modelling of Genetic Testing
Around 20-25% of ovarian cancers and 5-10% of breast cancers are due to an inherited predisposition. The primary clinical and economic benefit of hereditary breast and ovarian cancer (HBOC) testing is from preventing cancers in unaffected relatives who present for predictive/cascade testing for a known pathogenic variant in the family. Population-based genetic testing (GT) as an alternative to current practice has been gaining momentum, as it enables identification of high-risk women before they develop cancer. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: L. Petelin, M. Cunich, P. Procopio, C. Nickson, I. Campbell, A.H. Trainer Source Type: research

CN4 Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab Versus Chlorambucil PLUS Obinutuzumab for Treatment-Na ïve Chronic Lymphocytic Leukemia (ELEVATE-TN)
Report patient-reported outcomes of fatigue and health-related quality of life (HRQoL) from the randomized, phase 3, ELEVATE-TN study (NCT02475681) in patients with treatment-na ïve chronic lymphocytic leukemia (CLL). (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: P. Walker, J.P. Sharman, W. Jurczak, T. Munir, V. Banerji, S. Coutre, J. Woyach, G. Salles, W.G. Wierda, P. Patel, M.H. Wang, U. Emeribe, E. Flood, J.C. Byrd, P. Ghia Source Type: research

CO1 The Natural History, Clinical Outcomes and Unmet Needs of Patients with Arginase 1 Deficiency (ARG1-D): A Systematic Review of Case Reports
The objective of this study was to systematically review the literature to assess the natural history, clinical outcomes, and unmet needs of patients with ARG1-D. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: A. Bin Sawad, A. Pothukuchy, M. Badeaux, V. Hodson, G. Bubb, K. Lindsley, J. Uyei, G.A. Diaz Tags: Clinical Outcome Assessment Studies Source Type: research

CO2 Healthcare Utilization, Cost, and Quality Among High-Need, High-Cost Medicare Beneficiaries in Medicare Fee-for-Service Versus Medicare Advantage
The objective of this study was to identify high-need, high-cost cohorts of MAB and FFSB and compare their healthcare resource utilization, costs, and quality outcomes. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: C. Teigland, Z. Pulungan, I. Mohammadi Source Type: research

CO3 Comparison of Goal Attainment and Measures of Function in Two Dementia Clinical Trials.
Questionnaire-style outcome measures are often used in clinical trials. It is unclear whether this type of outcome measurement can capture change that is personally meaningful to individuals. In contrast, Goal Attainment Scaling (GAS) is an outcome measure where patients and clinicians develop and track an individualized set of treatment-related goals that are important to the patient. Here, we compared attainment of daily function goals to questionnaire-style measures of function in two mild-moderate dementia clinical trials. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: J. Stanley, S.E. Howlett, T. Dunn, S. Stanojevic, C. Chapman, K. Rockwood Source Type: research

CO4 Predictors of Inpatient Relapse in Multiple Sclerosis Patients Using First-Line Disease Modifying Therapies: A Machine Learning Study of Real World Data
This study aims to identify characteristics of inpatient MS relapse using claims data and machine learning techniques. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: Z. Icten, M. Friedman, J. Menzin Source Type: research

EC1 A Cost-Effectiveness Analysis of Nivolumab plus Ipilimumab plus Two Cycles of Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in the First-Line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer in the United States
To evaluate the cost-effectiveness of nivolumab plus ipilimumab plus two cycles of platinum doublet chemotherapy (NIVO+IPI+PDC) versus four cycles of PDC in the first-line (1L) treatment of stage IV or recurrent non-small cell lung cancer (NSCLC) from a health insurance perspective in the United States (US). (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: M. Polyzoi, H. Sandhu, J. Maervoet, Y. Yuan, M. Chaudhary, N. Varol, A. Lee, P. Dale, C. Jones, S.J. Lubinga, J.R. Penrod Tags: Economic Evaluation in Oncology Studies Source Type: research

EC2 Modeling Approaches to Estimate Realized Real Option Value of Ipilimumab in Metastatic Melanoma
Real option value (ROV) is created when a drug enables a patient to live long enough to benefit from a future innovation, but few if any studies have quantified ROV observed in the real world. We aimed to estimate the realized ROV using real-world data (RWD) using ipilimumab in melanoma as a case study. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: W. Lee, M. Li, W. Wong, T.M. To, L.P. Garrison, D. Veenstra Source Type: research

EC3 Economic Burden of Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia Treated with Novel Agents
Novel agent treatments (NATs) have improved survival in chronic lymphocytic leukemia (CLL), but can be associated with increased cardiovascular (CV) events. This analysis examined real-world healthcare costs associated with CV events in CLL patients treated with NATs. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: E. Malangone-Monaco, K. Ryan, E. Marchlewicz, J. Lo, S. Huntington Source Type: research

EC4 Real-World Healthcare Costs in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States
Patients with classical Hodgkin lymphoma (cHL) relapsed or refractory (R/R) disease incur substantial healthcare resource utilization and costs. The PD-1 inhibitors nivolumab and pembrolizumab were approved by the FDA (May 2016 and March 2017, respectively) as treatments for R/R cHL patients; however, literature on the healthcare costs of patients treated with these two medications is sparse. This retrospective study evaluated the medical costs of patients with cHL initiated on pembrolizumab compared to nivolumab in the US. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: F. Laliberte, M. Raut, G. Germain, K. Desai, A. Nahar, X. Yang, S. MacKnight, M.S. Duh Source Type: research

ED1 Antimicrobial Resistance in US Hospitals: Burden and VALUE of Investment in Developing New Treatments
This research aims to quantify the burden of antimicrobial resistance (AMR) from the perspective of hospital stakeholders and the value of continued investment in developing new treatments. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: W. Iacobucci, C.V. Siego, T. Dall, N. Wallin Bernhardsson, J. Ulrich, J.S. Dougherty Tags: Economic Evaluation Applications: Burden and Value of Therapies Source Type: research

ED2 Elements of Value for Gene Therapy: A Systematic Review
ISPOR recommends that value assessments include elements beyond traditional quality-adjusted life years (QALYs) and costs. We aimed to identify non-traditional value elements relevant to gene therapies as it is unclear to what extent they have been included in gene therapy value assessments. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: E. Kim, K. Raimundo, Z.A. Marcum, D.L. Veenstra Source Type: research

ED3 Societal Burden of Dementia-Related Psychosis in the US: A Cost of Illness Analysis
Dementia-related psychosis (DRP), characterized by hallucinations and delusions, may accelerate the cognitive/functional decline among patients with dementia. Such declines have debilitating consequences on patients, caregivers, and society. While previous research has estimated total annual-direct DRP costs, analysis of both direct and indirect costs is important in understanding the overall societal burden of DRP. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: K. Rajagopalan, N. Rashid, V. Abler, A. Shah Source Type: research

ED4 Economic Burden of Attention-Deficit/Hyperactivity Disorder (ADHD) Among Children and Adolescents in the United States (US): A Societal Perspective
To comprehensively assess the economic burden associated with ADHD among children and adolescents in the US in 2018. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: L.A. Adler, A. Childress, M. Cloutier, P. Gagnon-Sanschagrin, M. Davidson, F. Kinkead, A. Guerin, P. Lefebvre, J. Schein Source Type: research

EM1 When Are Breakthrough Therapies Cost-Effective?
The US Food and Drug Administration (FDA)-designated breakthrough therapies offer substantial potential to improve health outcomes, but it is unclear whether their health gains represent favorable value for money. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: N. Olchanski, P.J. Lin, D. Yeh, S. Kowal, J.T. Cohen Tags: Emerging Methods in Economic Evaluation Source Type: research

EM2 Economic IMPACT of Compassionate Use of Medicines
The economic impact of clinical trials in the perspective of trial sites has been already investigated. Instead, there is no evidence on the economic net benefit of compassionate use programs for medicines (CUP). This research aims to fill the information gap, investigating the economic consequences of ten CUPs in Italy carried out from May 2015 to April 2020 in the hospitals ’ perspective. These programs concern five cancer medicines used in different disease settings and two drugs for neurological disorders (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: C. Jommi, F. Pantellini, L. Stagi, M. Cavazza Source Type: research

EM3 Robustness of External Control Arm: WHEN to Use Them
During the COVID-19 pandemic, many aspects of traditional clinical trials have been affected worldwide. Recruitment of patients and on-site visits have been challenging when not compromised. Many groups have turned to the possibility of replacing their randomized standard of care (SOC) arm with a real-world (RW) external control arm (ECA). Unlike randomized controlled trials (RCTs) that have international guidelines, the use of an ECA is not subject to any consensus. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: M. Ladouceur, C. Colby, S. Okala, B. Yue Source Type: research

EM4 Recommendations for Handling Uncertainty in Economic Evaluation: A Targeted Review of Pharmacoeconomic Guidelines
The appropriate handling of uncertainty is an essential element of economic evaluation of healthcare interventions. Accepted methods include deterministic and probabilistic analyses to characterise parametric uncertainty, and scenario analyses to test uncertainty propagated by methodological and structural assumptions. This targeted review examined which methods for handling uncertainty are recommended in pharmacoeconomic guidelines around the world. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: V. Berdunov, C. Sammon, S. Ramagopalan Source Type: research

HP1 Validated Models for Pre-Test Probability of Stable Coronary Artery Disease: A Systematic Review Suggesting How to Improve Validation Procedures
An overuse of invasive and non-invasive anatomical testing for the diagnosis of coronary artery disease (CAD) affects patients ’ and healthcare professionals’ safety, and the sustainability of Healthcare Systems. Pre-test probability (PTP) models can be routinely used as gatekeeper for initial patient management. Several PTP models have been developed after the seminal work of Diamond and Forrester in the late 1970s, ho wever to assess their generalizability to different populations extended validation procedures should be carried out and their results carefully analyzed. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: A. Bodini, P. Mincarone, M.R. Tumolo, F. Vozzi, S. Rocchiccioli, G. Pelosi, C. Caselli, S. Sabina, C.G. Leo Tags: Hospital and Clinical Practice Studies Source Type: research

HP2 Patient-Provider Cost Discussions and out-of-Pocket Costs Among Cancer Survivors with Varying Levels of Cancer-Related Financial Hardships
This study examined whether cost discussions and financial hardships were related to out-of-pocket spending. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: H. Zhang, S. Zhang, S. Chen, J.C. Barner, L. Moczygemba Source Type: research

HP4 Dose Medicaid Expansion Provide Affordability of Helathcare Service for Asthma Population
The purpose of this analysis is to estimate the impact of Medicaid expansion in 2014 on healthcare services among asthma patients. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: L. Shi, J. Luck Source Type: research

HT1 Effects of Stakeholder Engagement with Icer on Cost-Effectiveness of New Interventions: Lessons Learned from a Critical Review of Evaluations from 2018 to 2019
The objective of this study is to evaluate the effectiveness of stakeholder engagemen t approaches and inform stakeholders of their potential role in collaborating with ICER. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: N. Ronquest, K. Paret, I. Gould, C.L. Barnett, D. Mladsi Tags: Health Technology Assessment Studies Source Type: research

HT2 Evaluation of Tucatinib for HER2-Positive Breast Cancer Patients with Brain Metastases: A United States-Based Cost-Effectiveness Analysis
To evaluate the cost-effectiveness of tucatinib in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) patients with brain metastases (BMs) and the subgroup of active BMs from the United States (US) payer perspective. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: L. Dong, D. Nian, Y. Huang, S. Lin, L. Zhong, X. Xu Source Type: research

HT3 What is Value? A Systematic Review of Value Assessment Frameworks
To investigate how value is defined and measured in existing value assessment frameworks (VAFs) in health care. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: M. Zhang, Y. Bao, Y. Lang, S. Fu, M. Kimber, M. Levine, F. Xie Source Type: research

HT4 Patient-Relevance of Endpoints Other Than Overall Survival (Non-OS Endpoints) in Oncology Health Technology Assessments by the Federal Joint Committee (G-BA) in Germany
To investigate the G-BA ’s decisions regarding patient-relevance of non-OS endpoints across breast cancer (BC), chronic lymphocytic leukaemia, melanoma, non-small cell lung cancer, ovarian cancer, and prostate cancer (PC). (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: N. Couybes, V. Agashe, W. Kulp, J. Ward Source Type: research

IN1 Treatment Journey of COVID-19 Patients in Hospital Settings
Severe cases of COVID-19 have overwhelmed hospital systems across the nation. To better understand patient ’s journey within hospital setting, this study described the treatment journey of COVID-19 patients from hospital admission to 30 days after discharge for inpatients and hospital-based outpatients. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: R. Moon, N. Rosenthal, H. Brown Tags: Impact of COVID-19 on Health Systems, Treatment, and Value Source Type: research

IN2 Characteristics of Patients Diagnosed with Coronavirus Disease 2019 (COVID-19) across the Three Waves in the US: A Claims-Based Study Using a Large National Sample
To assess how characteristics of patients diagnosed with COVID-19 have changed over the three waves in the US (April, July and November 2020) and evaluate the temporal relationship of disease severity. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: V. Divino Source Type: research

IN3 Economic VALUE and Health System IMPACT of Remdesivir in Treating Hospitalized COVID-19 Patients in the United States
This study evaluated remdesivir ’s long-term cost-effectiveness and impact on health system capacities versus standard of care (SoC) for hospitalized COVID-19 patients in the United States (US). (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: F. Sun, S. Jeyakumar, N. Smith Source Type: research

IN4 Non-Health Considerations in Economic Evaluations of COVID-19 Interventions: A Systemic Review
To examine whether and how economic evaluations for COVID-19 interventions incorporate non-health impacts. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: M. Podolsky, D. Kim, P.J. Neumann Source Type: research